OR WAIT null SECS
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
Activation and expansion are essential for success in both autologous and allogeneic therapies.
Continuous manufacturing and a quality-by-design development approach are a natural fit.
April 03, 2023
Despite the advantages intensified processes can offer developers, there are still some obstacles to overcome before broader application of new technologies will be implemented.
Impurities and batch-to-batch variability present the biggest challenges.
April 02, 2023
New child-friendly treatment options and initiatives are improving the outlook of children living with HIV in Europe.
FDA has spurred investment to create and develop 600 therapies.
Decreasing vein to vein time saves lives.
March 30, 2023
Takeda received approval in Japan for a subcutaneous injection formulation of Entyvio (vedolizumab) for treating ulcerative colitis.
Webinar Date/Time: Thursday, April 20th, 2023 4:00pm GMT | 11:00 am EDT | 5:00 pm CEST
March 28, 2023
Webinar Date/Time: Tue, Apr 25, 2023 11:00 AM EDT
March 24, 2023
Moderna and Generation Bio have announced a strategic collaboration to develop non-viral genetic medicines.
Curia is collaborating with Corning to advance biopharmaceutical continuous-flow development and manufacturing programs.